Conversely, loss of ARID1A may increase the risk of steatohepatitis and cancer progression by altering immunity in vivo or tumorigenesis via activation of angiopoietin-2 (ANGPT2) transcription in vitro and angiogenesis in vivo (2). This evidence concerns the gene ARID1A and cancer.